Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Immunotherapy Opdivo (Nivolumab) Non-Squamous NSCLC Trial Stopped, Reported as Positive
Author
Howard (Jack) West, MD

In January, 2015, the CheckMate 017 trial of the immune checkpoint inhibitor Opdivo (nivolumab) versus the standard chemo agent Taxotere (docetaxel) as second line therapy for patients with advanced squamous NSCLC was reported in a press release to be positive for a significant improvement in overall survival. No further details were offered at that time, but additional data were submitted to the FDA just days before the FDA approved Opdivo on March 4, 2015 and made it commercially available for these patients (with the FDA deserving credit for seemingly waiting in a conference room to go through an immediate approval process once the full data was supplied). We have since learned that Opdivo was associated with a significant, 3.2 month improvement in median overall survival, 9.2 vs. 6.0 months, but additional data await presentation at the annual ASCO meeting in Chicago in late May/early June.

Bristol-Myers-Squibb  (BMS) ran a parallel trial called CheckMate 057, also directly comparing Opdivo to docetaxel as second line therapy for patients with non-squamous NSCLC, which comprises about 75-80% of NSCLC patients in North America.  That trial completed enrollment around the same time as the squamous trial, but no results were forthcoming until this week, when a press release from BMS noted that an interim data review from this trial has demonstrated a significant survival benefit again for Opdivo -- with no additional data offered yet. 

What does this mean for lung cancer patients? Lung cancer specialists have been following the trials for years and had been very optimistic that both trials would emerge as positive for a survival benefit with Opdivo, but after the FDA approval of this agent for the minority of patients with squamous NSCLC, we could only be hopeful that we'd see the same pattern of a favorable press release, rapid FDA approval once submission of the relevant data to the FDA was completed, and then prompt availability of the agent to the much broader advanced NSCLC patient community...but at some undetermined point in the future.

We now have a starting point for the next timeline, which could lead us to an approval for in non-squamous NSCLC  by the time of the ASCO meeting, if not before. In the meantime, I hope to find that my requests for insurer coverage for Opdivo for my patients with chemotherapy-pretreated advanced non-squamous NSCLC may be granted more easily. I've spoken with colleagues who have had some success getting coverage for Opdivo for their non-squamous NSCLC patients, but with the FDA approval for Opdivo pretty much imminent, I'd like to find that insurers don't bother to pursue policies that are histology-specific, since that policy will have a short half-life.

In the meantime, it's great to be able to look forward to another therapy. As new immunotherapy agents and combinations try to find their way into the marketplace, there will now be a higher bar to clear, which is great for lung cancer patients.

Next Previous link

Previous PostNext Post

Related Content

Image
Blood Cancers OncTalk 2024
Video
  This event was moderated by Dr. Sridevi Rajeeve, Memorial Sloan Kettering, joined by speakers: Dr. Hamza Hashmi, Memorial Sloan Kettering, Dr. Michele Stanchina, University of Miami, Dr. Muhammad Salman Faisal, Oklahoma University, and Dr. Andrew Srisuwananukorn, Ohio State University Topics include: - Myeloma 101: Facts and Fiction of the 'Myeloma Marathon' - Updates in DLBCL - Treatment Basics of Bone Marrow Transplant - Frontline Therapies in Myelofibrosis - Panel Discussions and a Question-and-Answer session
Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.

Forum Discussions

Hi Stan,

It's so good to hear you and yours are doing well and that you were able to spend time with both families for Thanksgiving.  I know it meant a...

Hi Stan!  It is good to hear from you -- I am so very happy you are doing well.  I agree with Janine that family and friends - our chosen family...

Recent Comments

JOIN THE CONVERSATION
Hey Bluebird,

I understand…
By JanineT GRACE … on
So good to hear from you Stan
By dbrock on
Hi Stan,

It's so good to…
By JanineT GRACE … on